$AHS (AMN Healthcare Services Inc.)

$AHS {{ '2016-09-26T11:51:11+0000' | timeago}} • Announcement

$AHS' unit AMN Healthcare priced private offering of senior notes due 2024 and lifted offering size from $300MM to $325MM. The senior notes will bear an interest rate of 5.125% per annum and will be issued at 100% of their face value. The senior notes will be guaranteed by its affiliates that guarantee the company's credit facilities.

$HLS {{ '2017-10-20T14:46:12+0000' | timeago}} • Announcement

$HLS BoD declared a quarterly cash dividend on its common stock of $0.25 per share, payable on Jan. 16, 2018, to holders of record on Jan. 2, 2018.

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following an recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$ISRG {{ '2017-10-19T20:24:48+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical Earnings AlphaGraphic: Q3 2017 Highlights

$HCA {{ '2017-10-19T13:19:20+0000' | timeago}} • Announcement

$HCA updated its 2017 guidance. Revenues are expected to be $43-44Bil and diluted EPS is expected to be $6.45-6.70. Adjusted EBITDA is expected to be $8-8.15Bil while Capex is expected to be approx. $3Bil.

$HCA {{ '2017-10-19T13:19:05+0000' | timeago}} • Announcement

$HCA announced preliminary 3Q17 results. Revenues are expected to be approx. $10.696Bil vs. $10.270Bil in 3Q16. Net income attributable to HCA Healthcare, Inc. is expected to approximate $426MM or $1.15 per share compared to $618MM or $1.59 per share in 3Q16. Adjusted EBITDA is expected to approximate $1.776Bil.

$MD {{ '2017-10-18T14:51:29+0000' | timeago}} • Announcement

$MD announced the acquisition of Synergy Radiology Associates, PA, a private radiology physician group based in Houston, Texas. This marks the company's fourth radiology services practice acquisition in 2017.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

$ADP {{ '2017-10-05T21:53:31+0000' | timeago}} • Announcement

$ADP sends letter to stockholders urging them to vote on the White proxy card to re-elect all of the company's 10 highly qualified and experienced directors at its Nov. 7 Annual Meeting of Stockholders.

$RECN {{ '2017-10-05T16:10:26+0000' | timeago}} • Webcast

$RECN stated that during FY18, it will work through a variety of initiatives. The long-term goal is to be a 38-39% gross margin business with 27-28% in SG&A and 4-5% organic growth on an annualized basis.

$RECN {{ '2017-10-05T16:01:21+0000' | timeago}} • Webcast

$RECN expects the taskforce transaction to be substantially accretive to revenue and EBITDA from day one. The company expects taskforce to contribute $14-16MM annually in revenue and 10-12% EBITDA at its operating pace. The acquisition drove approx. $400,000 in acquisition costs in 1Q18.

$RECN {{ '2017-10-05T16:01:05+0000' | timeago}} • Webcast

Looking at $RECN’s early revenue trends for 2Q18, weekly revenues were trending 3% ahead of last year, excluding taskforce acquisition-related revenue. This includes the impact of approx. $350,000 in lost revenue from the hurricanes. Europe is doing well and Asia-Pacific is beginning to rebound after getting off to a slow start in 1Q18.

$RECN {{ '2017-10-05T16:00:44+0000' | timeago}} • Webcast

In October, $RECN will roll out the new operating model for sales within RGP for all of North America. The company has established the SCP program with dedicated account teams to lift revenue and target long-term global clients. $RECN also implemented its new sales process and technology platform SalesForce throughout the global business in 1Q18.

$ADP {{ '2017-10-05T15:56:17+0000' | timeago}} • Announcement

$ADP announced the acquisition of Global Cash Card, a player in digital payments, including paycards and other electronic accounts, for undisclosed terms. After integrating Global Cash Card with $ADP's existing paycard offer, the ALINE Card by ADP, $ADP will manage more than 4MM accounts on a single platform.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
RECN (Resources Connection, Inc.)
Wednesday, October 4 2017 - 9:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
THC (Tenet Healthcare Corp.)
Tuesday, August 8 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
SEM (Select Medical Holdings Corporation)
Friday, August 4 2017 - 1:00pm
KND (Kindred Healthcare Inc.)
Friday, August 4 2017 - 1:00pm
HSON (Hudson Global, Inc)
Thursday, August 3 2017 - 2:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
FVE (Five Star Quality Care Inc.)
Wednesday, August 2 2017 - 2:00pm
NSP (Insperity, Inc.)
Tuesday, August 1 2017 - 2:00pm
Tuesday, August 1 2017 - 2:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Tuesday, August 1 2017 - 1:30pm
Tuesday, August 1 2017 - 1:00pm
TBI (TrueBlue, Inc.)
Monday, July 31 2017 - 9:00pm
Friday, July 28 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm

AlphaGraphics you may like